Navigation Links
Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 14th Annual BIO CEO & Investor Conference in New York.   

The live presentation takes place on Monday, February 13 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2011 Results
2. Neurocrine Biosciences Reports Second Quarter 2011 Results
3. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
4. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
5. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
6. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
8. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
9. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
10. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... monetization of intellectual property, today announced that Chardan ... global investment bank specializing in micro, small, and ... Spherix. The report, authored by ... Chardan, was published on March 31, 2015. The ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Earlier this ... a vibrant life sciences industry association that represents research-based ... members. , Jonathan Parker, AJO’s Vice President of ... Dinner in February, an event that attracted over 750 ... Don Wright, a 73 year old cancer survivor shared ...
(Date:3/31/2015)... 31, 2015 CytoSorbents Corporation (NASDAQ CM: ... purification to treat critically-ill and cardiac surgery patients ... and reports financial results for the fiscal year ... CytoSorb® product revenues were a record $3.1M, an ... CytoSorb® revenues of $0.8M Highlights for the Year ...
(Date:3/31/2015)... Eastern Kentucky University is ranked ... of criminal justice degree programs by Nonprofitcollegesonline.com. , ... ideas and high quality educational opportunities,” Editor Liz ... We are confident that students will find both ... the site’s first “Students before Profits” list, and ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2
... Pharmaceuticals is,pleased to announce the introduction of ... on medically based aesthetics and,utilize the clinical ... of,science-based, result-oriented products., Vitivia(TM),s first product ... have long been recognized as important tools ...
... 27 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the establishment of ... Federale de Lausanne (EPFL), focusing on Signal ... million endowment, the objective,of the chair is ...
... combination vaccine against Ebola and Marburg viruses using ... infection in monkeys. Researchers from the U.S. ... report their results today (Feb. 26) at the ... in Baltimore, MD. , VLPs are one of ...
Cached Biology Technology:JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM) 2Debiopharm and EPFL Establish an Oncology Chair 2Combination vaccine protects monkeys from ebola and Marburg viruses 2
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Researchers at Loyola University Chicago Stritch School of ... the National Institutes of Health to study vitamin D ... evaluate the relation between low vitamin D levels and ... disease. Evidence from numerous previous studies is "inconclusive ...
... N.C. Researchers at the University of North Carolina at ... and paste together different viruses in an effort to create ... clinical trial, the investigators found no side effects from using ... muscle protein in patients with muscular dystrophy. "This trial ...
... Bethesda, MDUsing magnetic resonance imaging (MRI) and nanoparticle technology, ... the growth of laboratory-engineered blood vessels after they have ... step toward ensuring that blood vessels, and possibly other ... taking hold and working as expected. Until now, there ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2Yale researchers develop a way to monitor engineered blood vessels as they grow in patients 2
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
... Maker, 1. Modular system for large ... up to six lab-cast or precast ... with 18- or 24-cm Immobiline DryStrip ... gel cassettes.Innovative design simplifies loading and ...
ELF® 97 Immunohistochemistry Kit...
Biology Products: